FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events

[10-24-2011] The U.S. Food and Drug Administration (FDA) has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse events associated with the smoking cessation drug Chantix (varenicline).

https://www.fda.gov/Drugs/DrugSafety/ucm276737.htm

Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2018 Category: Drugs & Pharmacology Source Type: news